Atrinsic Goodwill and Intangible Assets 2010-2025 | PTIX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Atrinsic goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Atrinsic goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$249.5B
Amgen (AMGN)	$159.2B
Gilead Sciences (GILD)	$144.1B
Vertex Pharmaceuticals (VRTX)	$101.9B
Bristol Myers Squibb (BMY)	$98.6B
GSK (GSK)	$81.7B
CSL (CSLLY)	$69.9B
Regeneron Pharmaceuticals (REGN)	$63.4B
Alnylam Pharmaceuticals (ALNY)	$61.3B
Argenex SE (ARGX)	$40.6B
Insmed (INSM)	$28B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$21.2B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.9B
Genmab (GNMSF)	$16.1B
Genmab (GMAB)	$15.7B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.9B
Exelixis (EXEL)	$10.4B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Moderna (MRNA)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.5B
Halozyme Therapeutics (HALO)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8B